Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.
about
The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant womenPharmacokinetics of intravenous buprenorphine in children.Bioavailability of sublingual buprenorphine.Noninvasive drug delivery.Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment.Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity.Pharmacokinetic interactions between buprenorphine and antiretroviral medications.Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.[Pharmacotherapy of cancer pain : 2. Use of opioids.].Cancer pain management. Current strategy.[New modes of opioid administration.].Mandatory sublingual buprenorphine for postoperative pain.Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy.Buprenorphine in the treatment of opiate dependence.Morphine, pethidine and buprenorphine disposition in the cat.Plasma levels of opioid material in man following sublingual and intravenous administration of buprenorphine: exogenous/endogenous opioid interaction?Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.Development of mucoadhesive dosage forms of buprenorphine for sublingual drug delivery.The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements: in vitro proof of concept.Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.A comparison of intramuscular and sublingual buprenorphine, intramuscular morphine and placebo as premedication.Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects.Non-parenteral postoperative analgesia. A comparison of sublingual buprenorphine and morphine sulphate (slow release) tablets.[Drug therapy for tumor pain I. Properties of non-opioids and opioids.].Analgesics in patients with hepatic impairment: pharmacology and clinical implications.
P2860
Q30490602-8F715C40-4F9E-4612-AA12-381CA39815DEQ34000757-300E5E7D-4F25-4F91-AFE2-93B13BEF0666Q34397617-77387692-C27E-4AC7-951B-12BEFA09C3ACQ34417674-0B7FA680-6805-4F2A-960B-7A15F7C4C61DQ34477096-BBA216E4-13F9-4B48-8B9C-F4DAE07C269AQ35194946-5BEB20DB-2B36-4BB4-AEAB-C5CC2311015AQ35763921-B72B584F-BFE5-40C7-8B4C-7EA7CA996CDAQ36655057-9BC06229-2A73-4026-9172-FB21B2B51C8FQ37429615-C44AE039-28D8-4E71-BF59-7B43BF52E209Q37579953-3C57C400-5AD3-47EE-999F-CE39DED61AEDQ39477920-0CFCC4DE-FD62-44B9-BC0C-99E9B2FF4215Q39489632-7FD1BAD2-8214-40C1-897B-4A2BD5B8A2F2Q39491068-B58A7587-CAD5-431B-8022-13BD1EE6C730Q39554905-E15205CC-14DD-43CC-ADEC-0535C69540E1Q40178403-0634E98F-60DF-45F8-9290-8A61D1D6C650Q42962930-2892480E-E68F-4405-A898-60F46D454283Q43923568-2AFF12A3-CBCE-4304-A3AB-BA27DCBD0A50Q44345385-C4A51EDA-2EAB-4F15-A85A-648F935E0639Q44351187-0395DDD1-1279-4A9F-A788-7DDF5892AAA3Q44938774-F4D4E1B0-1C74-4F05-AA39-5F629462D4ECQ47556854-B06B646C-1BF0-40A8-B98C-AA8231F268D9Q48177006-7576070B-6FEB-4FED-9A13-C9C5A140C033Q50114873-02657D74-4486-45CA-B8A3-79E996DB4296Q51239893-D8C04C6B-91F8-4B6C-8330-24E4ACEB9B6BQ51529259-2C788EEE-0B59-4788-B7C2-6EDCD70B35A4Q51847279-830CC6C0-2A73-4771-B908-9BE1AB1EB652Q52292836-10A7B082-E3B0-48EA-9C9D-3834F0B4C906Q53689504-9086BE1B-A62F-4B5D-BE79-6CAB4787AE9C
P2860
Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.
description
1982 nî lūn-bûn
@nan
1982 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
name
Sublingual buprenorphine used ...... a drug concentration analysis.
@ast
Sublingual buprenorphine used ...... a drug concentration analysis.
@en
Sublingual buprenorphine used ...... a drug concentration analysis.
@nl
type
label
Sublingual buprenorphine used ...... a drug concentration analysis.
@ast
Sublingual buprenorphine used ...... a drug concentration analysis.
@en
Sublingual buprenorphine used ...... a drug concentration analysis.
@nl
prefLabel
Sublingual buprenorphine used ...... a drug concentration analysis.
@ast
Sublingual buprenorphine used ...... a drug concentration analysis.
@en
Sublingual buprenorphine used ...... a drug concentration analysis.
@nl
P2093
P2860
P1476
Sublingual buprenorphine used ...... a drug concentration analysis.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1982.TB01434.X
P407
P577
1982-05-01T00:00:00Z